Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11755MR)

This product GTTS-WQ11755MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11755MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11440MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ13716MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ8814MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ957MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ10558MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ10967MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ15119MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ12090MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW